Testing Warning Labels for Retail Cannabis Products Using a Discrete Choice Experiment
24 juillet 2026 mis à jour par: University of Oklahoma
Developing and Testing Warning Labels for Retail Cannabis Products
This discrete choice experiment (DCE) study aims to address gaps in cannabis packaging regulatory research by testing how variations in cannabis packaging and health warning design impact reactions to packaging and intentions about cannabis use.
The goal of this work is to identify the most effective combination of health warning features to improve consumer awareness of cannabis health risks.
Establishing criteria for cannabis products in the US is critical because inconsistent state guidelines have resulted in contradictory policies in legal retail states, arguably leading to increased hazardous use and failure to meet public health standards.
The contributions of this study's outcomes are expected to be significant because they will benefit public health as cannabis becomes available in legal retail markets and regulatory and governmental agencies seek effective ways to communicate cannabis risks to the public.
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Description détaillée
The DCE will be conducted via a self-administered online questionnaire, with inclusion criteria assessed before assignment to choice set conditions.
Participants will be residents of legal-retail cannabis use states, able to legally purchase cannabis (21 or older), who have used cannabis in the past 30 days (i.e., current use).
Frequency of cannabis use (i.e., monthly, weekly, daily), mode (e.g., flower, vape, etc.), and dose (i.e., THC level) will be measured through self-report.
Inclusion criteria are reported using cannabis (any mode) in the past 30 days.
Consented participants will be presented with descriptions of cannabis packaging attributes and an example choice set to become familiar with DCE tasks.
Participants will be asked to imagine the cannabis products in the DCE as the only choices they have available to them "in the near future" and to evaluate images within this scenario.
Participants will be randomly assigned to view 16 choice sets.
To optimize the evaluation of preferences and reduce respondent burden, we will assign contrasting labels to "choice sets," each of which will include 4 images of products in such a way that each attribute level appears an equal number of times in combination with all other attribute levels.
Presentation order of the 16 choice sets will be randomized within and across choice sets to minimize ordering effects.
Participants will view each choice set for as long as they wish.
After evaluating choice sets, participants will complete a recall task to assess retention of health warning information and will be provided a debrief page with information about substance use and resources for seeking help with substance use.
Type d'étude
Interventionnel
Inscription (Estimé)
450
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Zachary Massey, PhD
- Numéro de téléphone: 405-271-6872
- E-mail: zachary-massey@ou.edu
Lieux d'étude
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- University of Oklahoma
-
Contact:
- Zachary Massey, PhD
- Numéro de téléphone: 405-271-6872
- E-mail: zachary-massey@ou.edu
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Population étudiée
The study population consists of adults aged 21 years and older residing in U.S. states with legal retail cannabis markets (i.e., adult use non-medical or "recreational") who report cannabis use within the past 30 days.
Participants will be recruited from an online consumer research panel and will represent active adult cannabis consumers in these jurisdictions.
La description
Eligibility for participation includes: 1) being 21 years of age or older, 2) being able to speak and understand English, 3) self-reported having consumed cannabis in the last 30 days (any mode, e.g., flower, vape, edible, etc.), and 4) residing in a U.S. state or jurisdiction where retail (i.e., non-medical) cannabis use is legal.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Discrete choice experiment (DCE) cohort
Adult participants (21+) enrolled in this single-arm cohort will complete a computer-based discrete choice experiment during a single study visit (conducted online).
They will review a series of hypothetical cannabis products and select their preferred options.
|
A discrete choice experiment (DCE) consisting of 16 distinct choice sets.
Each choice set presents combinations of the following attributes: 1) Cannabis package style: 1) "Standardized" plain package, 2) plain package with brand logo and fonts, 3) brand color background with brand logo and fonts, and 4) fully branded with brand imagery, brand logo, and brand descriptors and fonts.
Branding type: 1) Adventure brand vs. 2) Earthy brand.
Health warning size: 1) Small (20% of packaging surface) - health warnings use currently mandated warning language from multiple jurisdictions vs. 2) Large (40% of packaging surface) - health warnings use currently mandated warning language from multiple jurisdictions.
Product THC content: 1) Low THC vs. 2) High THC.
Product type: 1) Joints, 2) Vape, 3) Edibles, and 4) Drinks.
Participants will rate all combinations of product attributes.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Risk perceptions about cannabis products
Délai: At the time of survey completion (approximately 15 minutes)
|
Binary measure using best-worst scaling.
For each question, participants will also have the option of indicating none of the above/opt-out as a response.
For each choice set, the statement selected as the best option will be coded using a value of 1, and the worst will be coded as -1.
The remaining statements in that set will be coded as 0. If the participant selects none of the above, all statements in that choice set will be assigned a value of 0.
|
At the time of survey completion (approximately 15 minutes)
|
|
Cannabis product use intentions
Délai: At the time of survey completion (approximately 15 minutes)
|
Binary measure using best-worst scaling.
For each question, participants will also have the option of indicating none of the above/opt-out as a response.
For each choice set, the statement selected as the best option will be coded using a value of 1, and the worst will be coded as -1.
The remaining statements in that set will be coded as 0. If the participant selects none of the above, all statements in that choice set will be assigned a value of 0.
|
At the time of survey completion (approximately 15 minutes)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Zachary Massey, PhD, University of Oklahoma
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
19 mai 2026
Achèvement primaire (Estimé)
31 décembre 2026
Achèvement de l'étude (Estimé)
31 décembre 2026
Dates d'inscription aux études
Première soumission
7 juillet 2026
Première soumission répondant aux critères de contrôle qualité
7 juillet 2026
Première publication (Réel)
14 juillet 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
27 juillet 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
24 juillet 2026
Dernière vérification
1 juillet 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 17276
- 1K01DA057395-01A1 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
INDÉCIS
Description du régime IPD
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .